mGlu4 PAM for the treatment of Parkinson’s disease (PD).
Parkinson’s disease, or PD is a progressive neurodegenerative disorder that is caused by loss of dopaminergic neurons in the basal ganglia, the brain center for movement initiation and coordination. mGlu4 receptors are strategically localized to counteract neurotransmitter imbalance and restore motor behavior in patients.
mGlu4 activation has been demonstrated to be effective in animal PD models, including the MPTP monkey model. Current treatments are aimed at replacing dopamine or mimicking its effects by chronically administering patients with the dopamine precursor L-DOPA, inhibitors of dopamine catabolic enzymes or direct dopamine receptor agonists.
Although these treatments provide good symptomatic relief in the early to middle stages of PD, they lose their efficacy as the disease progresses and their chronic administration is associated with disabling side effects (dyskinesia, motor fluctuations, behavior disturbances).
We believe our mGlu4 PAM program could be best-in-class and may offer an innovative and differentiated treatment approach from existing therapies.